Trial reportDiabetes, obesity & metabolism2026
A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.Diabetes, obesity & metabolism · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveTreatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified. Recent findings indicate that, in obese individuals, the kidney exhibits lower 18-fluorodeoxyglucose ([18F]-FDG) uptake rates compared to lean individuals, possibly due to insulin resistance. This post hoc analysis from our pilot study DAPAHeart aims to evaluate changes in cortical renal [18F]-FDG uptake in T2D patients following short-term treatment with dapagliflozin.
methodsIn our DAPAHeart trial, a single-centre, 4-week, prospective, double-blind, controlled study, we enrolled T2D patients with stable coronary artery disease and preserved glomerular filtration rates. Participants were randomly assigned in a 1:1 ratio to receive either dapagliflozin (10 mg daily) or a placebo. PET scans using [18F]-FDG were performed during a hyperinsulinemic-euglycemic clamp (HEC) to measure regional FDG uptake before and after the 4-week treatment with SGLT-2i.
resultsAfter 4 weeks of treatment, the between-group comparison (Mann-Whitney U test on change-from-baseline values) did not reach statistical significance for any SUV parameter. Nevertheless, a consistent directional pattern in renal standardised uptake value (SUV) was noted across all parameters, with reductions observed in the dapagliflozin group and stable or slightly increased values in the placebo group. The within-group analysis revealed a significant reduction in SUV_peak in the dapagliflozin group (p = 0.028), while no significant change was detected in the placebo group.
conclusionAlthough the primary between-group comparison did not reach statistical significance, likely due to the limited sample size (n = 7 per group), a consistent directional pattern was observed across all renal SUV parameters, with reductions in the dapagliflozin group and stable or slightly increased values in the placebo group. These findings suggest decreased glucose uptake in an insulin-stimulated state (HEC) in the dapagliflozin group. Although the causes of this reduction require further investigation, these preliminary findings support the hypothesis that SGLT-2 inhibition may reduce tubular energy requirements and glucose uptake, potentially contributing to the preservation of kidney function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.